missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ LanthaScreen™ TR-FRET RXR alpha Coactivator Assay Kit, goat
Description
This kit contains Goat Tb-Anti-GST antibody; other kit components are the same as kit A15138:
The LanthaScreen™ TR-FRET Retinoid X Receptor alpha Coactivator Assay provides a sensitive and robust method for high-throughput screening of potential RXR alpha ligands as agonists of ligand-dependent coactivator recruitment. The kit uses a terbium (Tb)-labeled anti- GST antibody, a fluorescein-labeled coactivator peptide, and a human recombinant RXR alpha ligand-binding domain (RXR alpha-LBD) that is tagged with glutathione-S-transferase (GST) in a homogeneous mix-and-read assay format.
To assay:
When running the LanthaScreen™ TR-FRET Retinoid X Receptor alpha Coactivator Assay in agonist mode (to identify agonist compounds), RXR alpha-LBD is added to ligand test compounds followed by addition of a mixture of the fluorescein-coactivator peptide and Tb-labeled anti-GST antibody. After an incubation period at room temperature, the TR-FRET ratio of 520/495 is calculated and can be used to determine the EC50 from a dose-response curve of the compound. Based on the biology of the RXR alpha-coactivator peptide interaction, this ligand EC50 is a composite value representing the amount of ligand required to bind to receptor, effect a conformational change, and recruit coactivator peptide (see Figure 1).
The LanthaScreen™ TR-FRET Retinoid X Receptor alpha Coactivator Assay provides a sensitive and robust method for high-throughput screening of potential RXR alpha ligands as agonists of ligand-dependent coactivator recruitment. The kit uses a terbium (Tb)-labeled anti- GST antibody, a fluorescein-labeled coactivator peptide, and a human recombinant RXR alpha ligand-binding domain (RXR alpha-LBD) that is tagged with glutathione-S-transferase (GST) in a homogeneous mix-and-read assay format.
To assay:
When running the LanthaScreen™ TR-FRET Retinoid X Receptor alpha Coactivator Assay in agonist mode (to identify agonist compounds), RXR alpha-LBD is added to ligand test compounds followed by addition of a mixture of the fluorescein-coactivator peptide and Tb-labeled anti-GST antibody. After an incubation period at room temperature, the TR-FRET ratio of 520/495 is calculated and can be used to determine the EC50 from a dose-response curve of the compound. Based on the biology of the RXR alpha-coactivator peptide interaction, this ligand EC50 is a composite value representing the amount of ligand required to bind to receptor, effect a conformational change, and recruit coactivator peptide (see Figure 1).
Specifications
Specifications
| Conjugate | Tb (Terbium) |
| Detection Method | Fluorescence |
| For Use With (Equipment) | Microplate Reader |
| Quantity | 800 x 20 μL assays |
| Packaging | 384-well Plate |
| Content And Storage | LanthaScreen™ TR-FRET RXR alpha Coactivator Assay Kits contain RXR alpha-LBD (GST) protein, fluorescently labeled PGC1a coactivator peptide, Tb-labeled anti-GST antibody and buffers. Store components as indicated in the assay protocol (-80°C, -20°C or 4°C). |
| Assay Entry | Biochemical coregulator interaction |
| Readout | End Point |
| Shipping Condition | Dry Ice |
| Target Entry | RXRA, RXR alpha, NR2B1 |
| Show More |
For Research Use Only. Not for use in diagnostic procedures.